Commentary|Articles|June 18, 2026

ASCO 2026 Breast Cancer Trials Affirm De-Escalation, Earlier Switching

Author(s)Coral O. Omene, MD, PhD, Sabrina Serani

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Several trials presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting reinforced a multiyear push toward de-escalating and individualizing breast cancer treatment, according to Coral Omene, MD, PhD, program director of Breast Cancer Disparities Research and a medical oncologist at Rutgers Cancer Institute, and associate professor of medicine at Rutgers Robert Wood Johnson Medical School.